Osaic Holdings Inc. Has $6.31 Million Stock Position in IDEXX Laboratories, Inc. $IDXX

Osaic Holdings Inc. grew its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 15.9% during the second quarter, according to the company in its most recent disclosure with the SEC. The fund owned 12,458 shares of the company’s stock after buying an additional 1,710 shares during the quarter. Osaic Holdings Inc.’s holdings in IDEXX Laboratories were worth $6,312,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of IDXX. Opal Wealth Advisors LLC acquired a new stake in shares of IDEXX Laboratories during the 2nd quarter valued at $29,000. WealthCollab LLC bought a new position in IDEXX Laboratories in the second quarter valued at about $30,000. Ameritas Advisory Services LLC bought a new position in IDEXX Laboratories in the second quarter valued at about $36,000. Elevation Point Wealth Partners LLC acquired a new stake in shares of IDEXX Laboratories during the second quarter valued at about $36,000. Finally, NewSquare Capital LLC grew its holdings in shares of IDEXX Laboratories by 87.5% during the second quarter. NewSquare Capital LLC now owns 75 shares of the company’s stock worth $40,000 after purchasing an additional 35 shares during the last quarter. 87.84% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on IDXX. Weiss Ratings reiterated a “buy (b-)” rating on shares of IDEXX Laboratories in a report on Monday, December 15th. Stifel Nicolaus set a $775.00 price target on shares of IDEXX Laboratories in a research report on Monday, November 3rd. Wall Street Zen downgraded shares of IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a research note on Saturday, November 29th. JPMorgan Chase & Co. lifted their price target on shares of IDEXX Laboratories from $675.00 to $775.00 and gave the stock an “overweight” rating in a report on Tuesday, November 4th. Finally, UBS Group boosted their price objective on shares of IDEXX Laboratories from $710.00 to $750.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 4th. Eight analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat, IDEXX Laboratories presently has an average rating of “Moderate Buy” and an average price target of $763.50.

Insider Buying and Selling

In other IDEXX Laboratories news, EVP Nimrata Hunt sold 9,425 shares of IDEXX Laboratories stock in a transaction that occurred on Friday, November 7th. The stock was sold at an average price of $703.34, for a total value of $6,628,979.50. Following the completion of the sale, the executive vice president directly owned 21,149 shares in the company, valued at approximately $14,874,937.66. The trade was a 30.83% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.98% of the stock is owned by corporate insiders.

IDEXX Laboratories Price Performance

Shares of NASDAQ IDXX opened at $702.12 on Tuesday. The company has a market capitalization of $56.06 billion, a PE ratio of 55.68, a P/E/G ratio of 4.18 and a beta of 1.67. The company has a quick ratio of 0.87, a current ratio of 1.18 and a debt-to-equity ratio of 0.24. IDEXX Laboratories, Inc. has a twelve month low of $356.14 and a twelve month high of $769.98. The firm has a fifty day simple moving average of $691.74 and a 200 day simple moving average of $628.25.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings results on Monday, November 3rd. The company reported $3.22 earnings per share for the quarter, topping analysts’ consensus estimates of $3.14 by $0.08. IDEXX Laboratories had a return on equity of 67.78% and a net margin of 24.65%.The firm had revenue of $1.11 billion during the quarter, compared to the consensus estimate of $1.07 billion. During the same period last year, the business posted $2.80 EPS. The business’s revenue was up 13.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2025 guidance at 12.810-13.010 EPS. On average, sell-side analysts forecast that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.